BACKGROUND: Genetic and epigenetic alterations are the two key mechanisms in the development of hepatocellular carcinoma (HCC). However, how they contribute to hepatocarcinogenesis and the correlation between them has not been fully elucidated. METHODS: A total of 48 paired HCCs and noncancerous tissues were used to detect loss of heterozygosity (LOH) and the methylation profiles of five tumor suppressor genes (RASSF1A, BLU, FHIT, CRBP1, and HLTF) on chromosome 3 by using polymerase chain reaction (PCR) and methylation-specific PCR. Gene expression was analyzed by immunohistochemistry and reverse transcription (RT)-PCR. RESULTS: Sixteen of 48 (33.3 %) HCCs had LOH on at least one locus on chromosome 3, and two smallest common deleted regions (3p22.3-24.3 and 3p12.3-14.2) were identified. RASSF1A, BLU, and FHIT showed very high frequencies of methylation in HCCs (100, 81.3, and 64.6 %, respectively) and noncancerous tissues, but not in liver tissues from control patients. Well-differentiated HCCs showed high methylation frequencies of these genes but very low frequencies of LOH. Furthermore, BLU methylation was associated with an increased level of alpha-fetoprotein, and FHIT methylation was inversely correlated with HCC recurrence. In comparison, CRBP1 showed moderate frequencies of methylation, while HLTF showed low frequencies of methylation, and CRBP1 methylation occurred mainly in elderly patients. Treatment with 5-aza-2'-deoxycytidine demethylated at least one of these genes and restored their expression in a DNA methylation-dependent or -independent manner. CONCLUSIONS: Hypermethylation of RASSF1A, BLU, and FHIT is a common and very early event in hepatocarcinogenesis; CRBP1 methylation may also be involved in the later stage. Although LOH was not too frequent on chromosome 3, it may play a role as another mechanism in hepatocarcinogenesis.
BACKGROUND: Genetic and epigenetic alterations are the two key mechanisms in the development of hepatocellular carcinoma (HCC). However, how they contribute to hepatocarcinogenesis and the correlation between them has not been fully elucidated. METHODS: A total of 48 paired HCCs and noncancerous tissues were used to detect loss of heterozygosity (LOH) and the methylation profiles of five tumor suppressor genes (RASSF1A, BLU, FHIT, CRBP1, and HLTF) on chromosome 3 by using polymerase chain reaction (PCR) and methylation-specific PCR. Gene expression was analyzed by immunohistochemistry and reverse transcription (RT)-PCR. RESULTS: Sixteen of 48 (33.3 %) HCCs had LOH on at least one locus on chromosome 3, and two smallest common deleted regions (3p22.3-24.3 and 3p12.3-14.2) were identified. RASSF1A, BLU, and FHIT showed very high frequencies of methylation in HCCs (100, 81.3, and 64.6 %, respectively) and noncancerous tissues, but not in liver tissues from control patients. Well-differentiated HCCs showed high methylation frequencies of these genes but very low frequencies of LOH. Furthermore, BLU methylation was associated with an increased level of alpha-fetoprotein, and FHIT methylation was inversely correlated with HCC recurrence. In comparison, CRBP1 showed moderate frequencies of methylation, while HLTF showed low frequencies of methylation, and CRBP1 methylation occurred mainly in elderly patients. Treatment with 5-aza-2'-deoxycytidine demethylated at least one of these genes and restored their expression in a DNA methylation-dependent or -independent manner. CONCLUSIONS: Hypermethylation of RASSF1A, BLU, and FHIT is a common and very early event in hepatocarcinogenesis; CRBP1 methylation may also be involved in the later stage. Although LOH was not too frequent on chromosome 3, it may play a role as another mechanism in hepatocarcinogenesis.
Authors: Angelo Agathanggelou; Ashraf Dallol; Sabine Zöchbauer-Müller; Catherine Morrissey; Sofia Honorio; Luke Hesson; Tommy Martinsson; Kwun M Fong; Michael J Kuo; Po Wing Yuen; Eamonn R Maher; John D Minna; Farida Latif Journal: Oncogene Date: 2003-03-13 Impact factor: 9.867
Authors: Nirmitha I Herath; Michael C Kew; Michael D Walsh; Joanne Young; Lawrie W Powell; Barbara A Leggett; Graeme A MacDonald Journal: J Gastroenterol Hepatol Date: 2002-03 Impact factor: 4.029
Authors: C T Liew; H M Li; K W Lo; C K Leow; J Y Chan; L Y Hin; W Y Lau; P B Lai; B K Lim; J Huang; W T Leung; S Wu; J C Lee Journal: Oncogene Date: 1999-01-21 Impact factor: 9.867
Authors: Carmen J Marsit; Duk-Hwan Kim; Mei Liu; Philip W Hinds; John K Wiencke; Heather H Nelson; Karl T Kelsey Journal: Int J Cancer Date: 2005-03-20 Impact factor: 7.396
Authors: Surbhi Jain; Lijia Xie; Batbold Boldbaatar; Selena Y Lin; James P Hamilton; Stephen J Meltzer; Shun-Hua Chen; Chi-Tan Hu; Timothy M Block; Wei Song; Ying-Hsiu Su Journal: Hepatol Res Date: 2014-12-09 Impact factor: 4.288
Authors: Jun Hou; Gertine van Oord; Zwier M A Groothuismink; Mark A A Claassen; Kim Kreefft; Fatiha Zaaraoui-Boutahar; Wilfred F J van IJcken; Albert D M E Osterhaus; Harry L A Janssen; Arno C Andeweg; Robert J de Knegt; Andre Boonstra Journal: J Virol Date: 2014-08-06 Impact factor: 5.103
Authors: Jean-Pierre Issa; Razelle Kurzrock; Ignacio I Wistuba; David J Stewart; Maria I Nunez; Jaroslav Jelinek; David Hong; Sanjay Gupta; Marcelo Aldaz Journal: Clin Epigenetics Date: 2014-07-03 Impact factor: 6.551